Amendment dated March 28, 2006 to the License Agreement by and between the Company and Georgia Regents Research Institute, Inc., formerly known as Medical College of Georgia Research Institut
Contract Categories:
Intellectual Property
- License Agreements
EX-10.1.4 6 nlnk-2019331x10qxex1014.htm EXHIBIT 10.1.4 Document
Exhibit 10.1.4
LICENSE AGREEMENT AMENDMENT
The following is an amendment to Exhibit A of the License Agreement between Medical College of Georgia and NewLink Genetics previously executed on September 13th, 2005. The purpose of this amendment is to explicitly list patent applications filed previously to the execution of this Agreement as continuations of Case # 009-03, and which were unintentionally ommited in the original Exhibit A. These missing patent applications are: Provisional US 60/538,647 and Non-Provisional Patents US 10/780,150 and US 10/780,797.
The present amendment should be considered part of the original License Agreement and is hereto agreed by representatives of both parties signing below.
| MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE | LICENSEE: NEWLINK GENETICS | ||||
By: /s/ Betty Aldridge | By: /s/ Nicholas Vahanian | ||||
Name: Betty Aldridge Executive Director MCG Research Institute | Name: Nicholas Vahanian | ||||
Title: | Title: Chief Medical & Operations Officer | ||||
Date: 3/28/06 | Date: 3/28/06 | ||||
EXHIBIT A
LICENSED PATENTS
[Case #007-98 | “Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. Patent No. 6,451,840 Inventors: D. Munn and A. Mellor | ||||
Case #007-98 Div1 | “Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. Patent No. 6,482,416 Inventors: D. Munn and A. Mellor | ||||
Case #007-98 Div2 | “Regulation of T-Cell Mediated Immunity by Tryptophan” U.S. non-Provisional/Regular Patent Application 10/112,362 Inventors: D. Munn and A. Mellor | ||||
Case #011-98 | High Affinity Tryptophan Transporter” U.S. Patent No. 6,395,876 Inventors: D. Munn and A. Mellor | ||||
Case #011-02 | “Antigen-Presenting Cell Populations and Their Use as Reagents for Enhancing of Reducing Immune Tolerance” U.S. non-Provisional/Regular Patent Application 10/121,909 Inventors: D. Munn and A. Mellor | ||||
Case #003-03 | “Chemokine Receptor Antagonists as Therapeutic Agents” U.S. non-Provisional/Regular Patent Application 10/660,131 Inventors: D. Munn, A. Mellor and S. Peiper | ||||
Case #009-03 | “Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase” U.S. Provisional Patent Application 60/459,489 Inventors: D. Munn and A. Mellor | ||||
Case #009-03 | “Inhibitors of Indoleamine-2,3-Dioxygenase and Methods of Use” U.S. Provisional Patent Application 60/538,647 Inventors: D. Munn and A. Mellor | ||||
Case #009-03 | “Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2,3-Dioxygenase” U.S. Non-Provisional/Regular Patent Application 10/780,150 Inventors: D. Munn and A. Mellor | ||||
Case #009-03 | “Use of Inhibitors of Indoleamine-2,3-Dioxygenase in Combination with Other Therapeutic Modalities” U.S. Non-Provisional/Regular Patent Application 10/780,797 Inventors: D. Munn and A. Mellor] | ||||
